(Q37638161)

21 August 2017

1 reference

title

Direct renin inhibition and the kidney (English)

1 reference

21 August 2017

Norman K Hollenberg

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

24 November 2009

1 reference

Nature Reviews Nephrology

21 August 2017

published in

1 reference

21 August 2017

volume

6

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

49-55

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2009.201

21 August 2017

exact match

0 references

cites work

Implications of species difference for clinical investigation: studies on the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Renin inhibition: what are the clinical perspectives?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Aliskiren accumulates in Renin secretory granules and binds plasma prorenin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Renin receptor blockade: a better strategy for renal protection than renin-angiotensin system inhibition?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

The preparation, purification, and amino acid sequence of a polypeptide renin substrate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Effects of blocking the angiotensin II receptor, converting enzyme, and renin activity on the renal hemodynamics of normotensive guinea pigs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Renal and endocrine responses to a renin inhibitor, enalkiren, in normal humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Aliskiren combined with losartan in type 2 diabetes and nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

The (pro)renin receptor: a new kid in town

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Human prorenin has "gate and handle" regions for its non-proteolytic activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.201

Prorenin and vascular complications of diabetes

31 March 2020

1 reference

12 December 2020

Renin vs. angiotensin-converting enzyme inhibition in the rat: consequences for plasma and renal tissue angiotensin

1 reference

12 December 2020

Microalbuminuria and increased plasma prorenin. Prevalence in diabetics followed up for four years

1 reference

12 December 2020

Molecular biology of renal injury: emphasis on the role of the renin-angiotensin system

1 reference

12 December 2020

Renal hemodynamic and excretory responses to renin inhibition induced by A-64662.

1 reference

12 December 2020

Renal vasodilatation after inhibition of renin or converting enzyme in marmoset.

1 reference

12 December 2020

The paradox of the low-renin state in diabetic nephropathy

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2009.201

1 reference

21 August 2017

1 reference